Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome

In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cells by immunohistochemistry staining (CD25...

Descripción completa

Detalles Bibliográficos
Autores principales: Prince, H. Miles, Martin, Ann G., Olsen, Elise A., Fivenson, David P., Duvic, Madeleine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523809/
https://www.ncbi.nlm.nih.gov/pubmed/22738414
http://dx.doi.org/10.3109/10428194.2012.706286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523809/
https://www.ncbi.nlm.nih.gov/pubmed/22738414
http://dx.doi.org/10.3109/10428194.2012.706286

Ejemplares similares